eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

vol. 43
Clinical immunology

Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia

Ahmet Mentese, Nergiz Erkut, Selim Demir, Serap Ozer Yaman, Aysegul Sumer, Mehmet Erdem, Ahmet Alver, Mehmet Sonmez

(Centr Eur J Immunol 2018; 43 (3): 276-280)
Online publish date: 2018/10/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Cancer is the second most important cause of mortality, and millions of people either have or have had the disease. Leukaemia is one of the most common forms of cancer. Autoantibodies that have developed against the organism’s self-antigens are detected in the sera of subjects with cancer. In recent years carbonic anhydrase (CA) autoantibodies have been determined in some autoimmune diseases and carcinomas, but the mechanisms underlying this immune response have not yet been fully explained. The purpose of this study was to determine CA I and II autoantibodies in subjects with chronic lymphocytic leukaemia (CLL) and to provide a novel perspective regarding the autoimmune basis of the disease. Autoantibody levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 37 patients with CLL and 37 healthy peers. Anti-CA I titres in the CLL group were significantly higher compared with the control group (p = 0.0001). However, there was no significant difference between CLL and control groups in terms of anti-CA II titres (p = 0.278). The prevalences of CA I and II autoantibodies in patients with CLL in this study were 27% and 24.3%, respectively. Our results suggest that these autoantibodies may be involved in the pathogenesis of CLL. More extensive studies are now needed to reveal the entire mechanism.

autoantibody, cancer, carbonic anhydrase, chronic lymphocytic leukaemia

Hodgson K, Ferrer G, Montserrat E, et al. (2011): Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 96: 752-761.
Ghia P, Ferreri AJM, Caligaris-Cappio F (2007): Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 64: 234-246.
Siegel RL, Miller KD, Jemal A (2016): Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.
Mauro FR, Foa R, Cerretti R, et al. (2000): Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features. Blood 95: 2786-2792.
Kipps TJ, Carson DA (1993): Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81: 2475-2487.
Abu-Shakra M, Buskila D, Ehrenfeld M, et al. (2001): Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60: 433-441.
Chapman CJ, Murray A, McElveen JE, et al. (2008): Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63: 228-233.
Zhong L, Ge K, Zu JC, et al. (2008): Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 10: R40.
Lowe FJ, Shen W, Zu J, et al. (2014): A novel autoantibody test for the detection of pre-neoplastic lung lesions. Mol Cancer 13: 78.
Gokcen T, Gulcin I, Ozturk T, et al. (2016): A class of sulfonamides as carbonic anhydrase I and II inhibitors. J Enzyme Inhib Med Chem 29: 1-9.
Leppilampi M, Koistinen P, Savolainen ER, et al. (2002): The expression of carbonic anhydrase II in hematological malignancies. Clin Cancer Res 8: 2240-2245.
Adamus G (2009): Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 8: 410-414.
Alver A, Senturk A, Cakirbay H, et al. (2011): Carbonic anhydrase II autoantibody and oxidative stress in rheumatoid arthritis. Clin Biochem 44: 1385-1389.
Mentese A, Erkut N, Sumer A, et al. (2015): Anti-carbonic anhydrase antibodies in iron deficiency anemia. Hematology 20: 363-367.
Binet JL, Auquier A, Dighiero G, et al. (1981): A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206.
Rai KR, Sawitsky A, Cronkite EP, et al. (1975): Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234.
Kino-Ohsaki J, Nishimori I, Morita M, et al. (1996): Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren’s syndrome. Gastroenterology 110: 1579-1586.
Zhang JY, Casiano CA, Peng XX, et al. (2003): Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12: 136-143.
Vedeler CA, Antoine JC, Giometto B, et al. (2006): Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13: 682-690.
Duek A, Shvidel L, Braester A, et al. (2006): Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J 8: 828-831.
Alver A, Mentese A, Karahan SC, et al. (2007): Increased serum anti-carbonic anhydrase II antibodies in patients with Graves’ disease. Exp Clin Endocrinol Diabetes 115: 287-291.
Karahan SC, Guven S, Mentese A, et al. (2009): Serum anti-carbonic anhydrase I and II antibodies and idiopathic recurrent pregnancy loss. Reprod Biomed Online 19: 859-863.
Turk A, Aykut M, Akyol N, et al. (2014): Serum anti-carbonic anhydrase antibodies and oxidant-antioxidant balance in patients with acute anterior uveitis. Ocul Immunol Inflamm 22: 127-132.
Demir C, Demir H, Esen R, et al. (2010): Erythrocyte catalase and carbonic anhydrase activities in acute leukemias. Asian Pac J Cancer Prev 11: 247-250.
Parkkila S, Lasota J, Fletcher JA, et al. (2010): Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23: 743-750.
Iuchi Y, Okada F, Onuma K, et al. (2007): Elevated oxidative stress in erythrocytes due to a SOD1 deficiency causes anaemia and triggers autoantibody production. Biochem J 402: 219-227.
Iuchi Y, Okada F, Takamiya R, et al. (2009): Rescue of anaemia and autoimmune responses in SOD1-deficient mice by transgenic expression of human SOD1 in erythrocytes. Biochem J 422: 313-320.
Dalle-Donne I, Scaloni A, Giustarini D, et al. (2005): Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 24: 55-99.
Amara A, Constans J, Chaugier C, et al. (1995): Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol 101: 233-238.
Toyoda K, Nagae R, Akagawa M, et al. (2007): Protein-bound 4-hydroxy-2-nonenal: an endogenous triggering antigen of antI-DNA response. J Biol Chem 282: 25769-25778.
Uchida K, Hasui Y, Osawa T (1997): Covalent attachment of 4-hydroxy-2-nonenal to erythrocyte proteins. J Biochem 122: 1246-1251.
Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. (1992): Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887.
Cvetkovic JT, Wallberg-Jonsson S, Ahmed E, et al. (2002): Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) 41: 988-995.
Ben Mansour R, Lassoued S, Elgaied A, et al. (2010): Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies. Scand J Rheumatol 39: 247-253.
Winyard PG, Ryan B, Eggleton P, et al. (2011): Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochem Soc Trans 39: 1226-1232.
Djurdjevic P, Zelen I, Ristic P, et al. (2006): Oxidative stress markers in chronic lymphocytic leukemia. Medicus 7: 52-56.
Ortin X, Giralt M, Romeu M, et al. (2012): Oxidative stress in patients with early stage chronic lymphocytic leukemia, assessment and correlation with prognostic factors. J Hematol 1: 77-88.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe